Ardelyx

Ardelyx

Pharmaceuticals
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

$902.1M

Market Cap • 9/22/2026

2007

(19 years)

Founded

2014

(12 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

6,1

P/S

2

P/EBITDA

P/OCF

P/FCF

P/E

BVPS

0,6

EPS

Market Cap

Market Cap

902,1M

EV

876,4M

EV/Revenue

1,9

EV/EBITDA

-27,3

EV/EBIT

-24,7

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-1,2%

Total Yield

-1,2%

Payout

0%

Retained Earnings

-1B

Profitability

Gross Margin

94,4%

EBITDA Margin

EBIT Margin

Net Margin

D&A/EBITDA

0%

R&D/Revenue

19,3%

Capex/Revenue

0,1%

Capex/D&A

17,9%

Capex/OCF

-3,5%

SBC/OCF

% PPE

1%

% Goodwill

0%

ROE

ROIC

Growth

CAGR Revenue 5Y

105,1%

CAGR Op. Income 5Y

-21,9%

CAGR Net Income 5Y

-15%

CAGR EPS 5Y

-29,4%

CAGR OCF 5Y

-31,6%

Leverage

N.D./EBITDA

0,8

Debt/Equity

0%

Current Ratio

3,3

Quick Ratio

2,9

Interest Coverage

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium